skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of glucocorticoids-induced osteoporosis: role of teriparatide

Review

(2376) Views  (866) Full article downloads

Authors: Silvia Migliaccio, Marina Brama, Nazzarena Malavolta

Published Date April 2009 Volume 2009:5 Pages 305 - 310
DOI: http://dx.doi.org/10.2147/TCRM.S3940

Silvia Migliaccio1, Marina Brama1, Nazzarena Malavolta2

1Dipartimento di Fisiopatologia Medica, Policlinico Umberto I, Università degli Studi Sapienza di Roma, Italy; 2Dipartimento di Medicina Interna, Policlinico S Orsola Malpighi, Bologna, Italy

Abstract: Glucocorticoids (GC)-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis, which leads to an increased fracture risk in patients. The normal bone turnover depends on a balance between osteoblasts and osteoclasts activity and GC can cause a rapid bone loss, decreasing bone formation and increasing bone resorption. The decreased bone formation is mainly due to the GC-induced apoptosis of both osteoblasts and osteocytes, while the increased bone resorption is due to the increased life-span of pre-existing osteoclasts. Bisphosphonates are clearly effective in preventing and treating GIOP but anabolic therapeutic strategies are the new promising therapeutic alternative. Experimental and clinical studies indicate that teriparatide, the active (1–34) parathyroid hormone (PTH) molecule, is efficacious for the treatment of GIOP, being able to induce an increase in bone mass in these patients. Intermittent administration of human PTH (1–34) stimulates bone formation by increasing osteoblast number. Additionally, human PTH (1–34) modulates the level and/or activity of locally produced growth factors and cytokines. Teriparatide has been demonstrated in several clinical studies to significantly decrease the incidence of fractures in patients affected by GIOP. It has recently received an indication for GIOP and its label indication has also been expanded.

Keywords: glucocorticoids, osteoblasts, osteoclasts, osteoporosis, teriparatide






 

Other articles by Dr Silvia Migliaccio



Readers of this article also read:

Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Health literacy and health seeking behavior among older men in a middle-income nation
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Everolimus-eluting stents: update on current clinical studies
Clinical features and treatment of maturity onset diabetes of the young (MODY)